Pfizer Aromasin Cleared For Early Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy